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Abstract: Hypoxia and Inflammation are strictly interconnected with important consequences at 
clinical and therapeutic level. While cell and tissue damage due to acute hypoxia mostly leads to cell 
necrosis, in chronic hypoxia, cells that are located closer to vessels are able to survive adapting their 
phenotype through the expression of a number of genes, including proinflammatory receptors for 
alarmins. These receptors are activated by alarmins released by necrotic cells and generate signals for 
master transcription factors such as NFkB, AP1, etc. which control hundreds of genes for innate 
immunity and damage repair. Clinical consequences of chronic inflammatory reparative response activation include cell 
and tissue remodeling, damage in the primary site and, the systemic involvement of distant organs and tissues. 
Thus every time a tissue environment becomes stably hypoxic, inflammation can be activated followed by chronic 
damage and cell death or repair with vessel proliferation and fibrosis. This pathway can occur in cancer, myocardial 
infarction and stroke, diabetes, obesity, neurodegenerative diseases, chronic and autoimmune diseases and age-related 
diseases. Interestingly, proinflammatory gene expression can be observed earlier in hypoxic tissue cells and, in addition, 
in activated resident or recruited leukocytes. 
Herewith, the reciprocal relationships between hypoxia and inflammation will be shortly reviewed to underline the 
possible therapeutic targets to control hypoxia-related inflammation in a number of epidemiologically important human 
diseases and conditions. 
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HYPOXIA AND ADAPTATION TO HYPOXIA 
 Hypoxia is a reduction of normal level of tissue oxygen 
tension, occurring for several reasons in some physiological 
processes such as early embryonic growth or stem cell niche 
maintenance [1] and in a number of pathological conditions 
such as infarction, tumors, diabetes, obesity, pathological 
hypertrophy, neurodegenerative diseases and many others 
[1]. 
 Hypoxia has two effects: 1-necrosis of cells in the region 
more distant from tissue vessels. 2-adaptation of cells in the 
region along the hypoxic gradient close to the vessels. 
Necrosis: the O2 shortage causes inhibition of ATP production, 
rapid fall of the energy charge, and loss of ionic gradients 
with the alteration of cytosolic calcium homeostasis [2, 3]. 
The increase of cytosolic Ca++ concentration above 10-6 M, 
dramatically activates the peroxidative metabolism [2], an 
irreversible contraction and degradation of the cytoskeleton 
[3, 4] and the activation of Ca++-dependent cytosolic proteases 
(calpains) and DNA-ases [5, 6], all leading to a rapid and 
irreversible cell degradation. Plasmamembrane rupture  
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due to lipoperoxidation is responsible for the definitive loss 
of the ionic gradients and for the release of intracellularly 
segregated molecules, many of which are called alarmins for 
their ability to signal the cell damage to specific receptors on 
adjacent cells. Adaptation of cells surviving to the hypoxia 
(when they are closer to the vessels) occurs through the 
activation of HIF1α and the expression of a number of 
genes, such as VEGF, Glut1 and HKII, TERT [7], stemness 
genes and, very importantly in our case, endogenous alarmin 
receptors, such as RAGE, P2X7 [8], Toll-like receptors [9], 
NOD-like receptors [10], etc. (Fig. 1). The beneficial effects 
of these genes can be observed in multiple cell or tissue 
functions and include: vasodilatation and neoangio- 
genesis to increase the local blood supply, metabolic shift 
from oxidative mitochondrial metabolism to anaerobiotic 
glycolysis, activation of telomerase in stem cells, 
reprogramming somatic cells to stem cells [11]. 
 Importantly, alarmins (Table 1) released by necrotic cells 
(HMGB1, ATP/ADP, membrane debris, nucleic acids, etc.) 
bind their receptors and activate NFkB with the expression 
of hundreds of genes of the inflammatory reparative 
response (IRR) [for ref. see Table 1]. Therefore, non 
leukocytic cells in hypoxic tissue microenvironment can 
present a NFkB-dependent proinflammatory gene response 
similar to that seen in activated leukocytes (Fig. 1). 
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INFLAMMATION OR INNATE DEFENSIVE AND 
REPARATIVE RESPONSE (IRR) 
 Inflammation is a tissue/cell response to a noxious agent 
and/or to a cell damage to protect, defend, repair and limit 
the harm of the organism. Acute inflammation was already 
well known to Hyppocrates and thereafter precisely 
described by Galeno as acute phenomenon with prevalent 
vascular involvement. The modern picture is more complex 
and detailed due to the knowledge of pathways and 
molecular players for its local activation, specific tissue 
reactions, production of effectors, recruitment of distant 
cells, systemic involvement, production of damage, fine 
tuning regulation, and inhibition of progression for 
resolution and repair. 
 IRR may result inadequate (that is ineffective in 
protecting and repairing), chronic (that is prolonged), 
inopportune (when activated untimely and awkwardly), 
excessive (when is not rightly controlled) during one or all 
its phases [12]. In these situations IRR is clinically chronic 
and contributes substantially to host damages, causing 
multiorgan dysfunctions. In the progression of IRR it is 
possible to recognize typical signs and symptoms such as the 
accumulation of exudate, fever, leukocyte infiltration, excess 
of ROS production, damage to surrounding tissue, and a 
continuous fibrotic repair which leads to fibrosis and to 
organ insufficiency [12]. 
 Inflammation is triggered by exogenous damaging 
agents such as viruses, bacteria, fungi, other pathogens and 
extraneous agents, presenting on their surface characteristic 
chemical pattern (Pathogen-Associated Molecular Patterns or 
PAMPs), or by endogenous signals (Damage-Associated 
Molecular Patterns or DAMPs) [13], which are usually 
released by damaged cells (necrosis, membrane shedding, 
exosomes, apoptosis) (Table 1). Collectively PAMPs and 
DAMPs are also known as alarmins [14-22]. These 
 
Fig. (1). Bridging hypoxia and inflammation in some human chronic diseases. HIF/NFkB-directed gene expression and phenotype 
remodeling. For HIF-directed adaptation, only representative genes are indicated. For NFkB, activated genes can vary depending on 
cell/tissue, therefore, for simplicity, we have indicated only the involved gene family. Representative references are indicated. Alternative 
pathways for hypoxia-associated NFkB activation and NFkB-dependent HIF activation are indicated. 
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pleomorphic molecules activate, with different specificity, a 
number of receptors belonging to highly conserved families 
with diverse signaling pathways, converging in the activation 
of NFkB, AP-1 and other TFs which are recognized as the 
major players in the inflammation, controlling all the genes 
participating to this response [13, 23]. 
 Alarmin receptors (ARs) were firstly localized in tissue 
resident leukocytes [13, 14], but at present have been 
described in many other cells and tissues [13]. In fact, there 
are evidences that alarmin receptors can be induced and 
expressed de novo in resident or recruited stem cells and 
pluripotent undifferentiated progenitors from many tissues, 
under stressing conditions such as acute or chronic hypoxia 
[24] and cellular ROS increase [25, 26]. ARs after sensing 
alarmins generate a signal cascade that activates NFkB (or 
other TFs), leading to the expression of genes belonging to 
the large families of the IRR, all involved in defence, 
protection and repair of cell and tissues (Table 1). 
 Another molecular component of the innate response is 
inflammasome constituted by large protein complexes 
assembled by cytosolic alarmin receptors (NOD-like 
receptors or NLRs) activated into the cytosol [27, 28]. While 
surface membrane alarmin receptors interact with signals 
coming from extracellular space (of exogenous origin or 
released by damaged cells), inflammasomes are activated by 
intracellular molecules already present in damaged, stressed 
or aged cells. Examples of these molecules include 
monosodium urate crystals (gout), cholesterol crystals 
(hypercholesterolemia and atherosclerosis), islet amyloid 
polypeptide (stored in the pancreatic beta cells in type 2 
diabetes) [28], viral and bacterial DNA and simpler 
molecules such as ATP, HMGB1 and membrane 
phosphatidylserine which become available in damaged or 
dying cells as membrane debris. Activated NLRs respond 
rapidly to different cytosolic PAMPs and DAMPs, recruiting 
and activating pro-caspase-1 and other pro-inflammatory 
caspases [27]. Caspase-1 activates the major pro-
inflammatory cytokines (IL-1 and IL-18) and is also 
responsible for degradation of many target proteins, 
contributing to cell degradation [19, 27]. Defects in the 
structure and activity of inflammasomes can be responsible 
for a large number of chronic human diseases, including 
chronic arthritis, Crohn’s disease, irritable bowel and other 
inflammatory diseases, diabetes, metabolic syndrome, cancer 
and ageing [12, 19, 29, 30]. Targeting these proteins 
represents an additional new therapeutic strategy for these 
pathologies [12, 31]. 
Effectors and Cytokine Storm 
 Inflammation or innate immunity involve signaling 
pathways leading to the production of inflammatory 
mediators or effectors in a cell-specific manner. Examples 
are classical mediators such as histamine, prostaglandins, 
leukotrienes, lipoxins, plasmalogens, cytokines, chemokines, 
reactive oxygen intermediates (ROI), reactive nitrogen 
intermediates (RNI), and anti-inflammatory molecules  
(IL-10, A20, IL-1RA). Sometimes a massive production of 
proinflammatory cytokines (cytokine storm) occurs leading 
to multiorgan irreversible damage and shock [1, 31]. As a 
matter of fact, all the effectors are a double-edge sword, 
having from one side an exquisite protective role to defeat 
invaders and limiting the harm of the host, from the other 
hand when their action is excessive or improper they can be 
the driving force responsible for tissue/organ damages. 
During inflammation a production of numerous ROI, RNI 
and chlorine species occurs, in addition to the products of 
lipid and sugar oxidation [32,33]. Most of these products are 
capable of chemically modifying protein amino acids, 
changing the structure, folding and function of proteins. 
Increasing evidence demonstrates that such oxidative post-
Table 1. Alarmins and their receptors activating inflammation.  
Exogenous Alarmins (PAMPs)	   Receptors (Ref. 12, 13, 59)	   References 
- Viruses	   TLR3, TLR7, TLR8, TLR9	   [13, 59] 
- Bacteria	   CD14, TLR2, TLR4, TLR5, TLR9, TLR11	   [13, 59] 
- Fungi and protozoa	   TLR2, TLR4, others	   [13,59] 
- Obligate Intracellular pathogens 	   NOD-like receptors (NLRs) and intracellular TLRs 	   [19, 58] 
-Intracellular fibers (such as asbestos fibers)	   NOD-like receptors (NLRs)	   [19, 20] 
Endogenous alarmins	   Receptors	   [12, 55] 
HMGB1	   RAGE, TLR2, TLR4	   [12, 55] 
ATP/ADP	   P2X7, (other P2X and P2Y receptors?)	   [55, 56] 
Oxidized phospholipids and Phosphatidyl-serine Pattern	   TLRs (?)	   [57] 
Crystals (cholesterol, uric acid, etc.)	   NOD-like receptors (NLRs) and intracellular TLRs (TLR2, TLR4, CD14)	   [19] 
dsDNA – dsRNA virali citosolici	   RIG-like helicases (RLHs), TLR9	   [55] 
Defensins and cathelicidins	   TLR4+CCR6, and FPRL1	   [55] 
Heat shock proteins	   CD14, CD91, TLR2, TLR4, CD40	   [55] 
References are indicated and discussed in the text. PAMPs = pathogen associated molecular patterns; DAMPs = damage associated molecular patterns; TLRs = Toll-like receptors; 
CCR6 = chemokine receptor 6; FRLP1 = formyl peptide receptor-like 1. 
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translational modifications may generate neo-epitopes 
capable of eliciting both innate and adaptive immune 
responses giving origin to autoimmune diseases such as 
systemic lupus erythematosus, rheumatoid arthritis, chronic 
bowel diseases and others [25]. Some new epitopes 
generated by oxidation are conserved along evolution as 
pathogen-associated molecular patterns (PAMPs) [25]. 
IRR Regulation 
 Usually inflammatory response is self-limiting and well 
controlled, but in the presence of improper activation, 
aberrant amplification, mutated alarmin receptors or 
inflammasomes, inhibited or delayed resolution results in 
chronic diseases. Much attention has been focused on pro-
inflammatory signaling but the precise mechanisms leading 
to the inhibitory control of inflammation is still unclear [34]. 
 The IkB kinase (IKK) complex contains two catalytic 
subunits, IKKα and IKKβ, and controls the activation of 
NFkB transcription factors, the pivotal actor/controller of the 
inflammation [34, 35]. NFkB activation and activity 
persistence are tightly controlled by a number of endogenous 
mechanisms that limit the excessive and prolonged 
production of pro-inflammatory mediators and the associated 
tissue damage [35]. 
 NFkB (nuclear factor kB) is a transcription factor that 
controls and modulates the expression of genes involved in 
both the innate and adaptive immune response [34]. The 
regulatory ability of NFkB is controlled by post-
transcriptional modifications such as phosphorylation and 
complex interactions with other cytosolic and nuclear 
proteins. Upon activation of the NFkB signaling pathway, 
IkB kinases target IkBs for degradation. This allows NFkB 
to translocate and accumulate in the nucleus, where it binds 
to DNA, resulting in the expression of target genes [34-36]. 
One of the genes activated by NFkB is that encoding IkB. 
Newly synthesized IkB binds to NFkB and attenuates the 
pathway of response to alarmin receptors, thereby creating a 
negative feedback loop within this signaling pathway [35]. 
SOCS gene family is another major regulator of IRR once 
activated. Seven SOCS members have been identified but in 
particular SOCS-1 inhibits the cytokine signaling via Janus 
kinase (JAK) and STAT, efficiently negatively regulating 
NFkB-directed proinflammatory expression. 
 Most of the times, the IRR starts locally at the damaged 
site, and then rapidly eliminate the invading pathogen and/or 
repair the damaged cell and tissues. However, if the local 
activation is strong and the release of mediators (such as 
eicosanoids and cytokines) is abundant, distant leukocytes 
and cells are recruited, thus amplifying the response at 
systemic level. The necrosis of damaged tissues, such as in 
hypoxic tumours, contributes to the IRR amplification 
further activating resident leukocytes and recruiting the 
peripheral ones [37, 38]. 
 In summary IRR is a complex response to a pathogen or 
to a cell damage in which inflammatory cells (chiefly 
leukocytes and endothelial cells, but also tissue cells) are 
activated and express a specific set of genes named 
“proinflammatory genes” acting to defend against pathogens, 
protecting and repairing damaged cells. Proinflammatory 
gene expression has been observed also in hypoxic tissue 
cells, especially stem cells and less differentiated 
progenitors, and appears basically similar to that of activated 
leukocytes. 
HYPOXIA AND INFLAMMATION IN HUMAN 
PATHOLOGY 
 A large number of evidences suggest that when a tissue 
environment becomes stably hypoxic, inflammation can be 
activated causing chronic damage and cell death as well as 
repair with vessel proliferation and fibrosis. This pathway, 
with some variations, can occur in many important human 
pathologies such as cancer, infarction, diabetes, obesity, 
pathologic hypertrophy, neurodegenerative diseases,  
chronic and autoimmune diseases and age-related diseases. 
Interestingly, both HIF-dependent adaptation and 
proinflammatory gene expression can be observed very early 
in these conditions and have been shown more evidently in 
local hypoxic stem cells and progenitors [39]. 
 In the next paragraphs a rapid overview is presented on 
how hypoxia originates in different pathologic conditions 
and how this leads to the inflammation. 
Hypoxia and Inflammation in Cancer 
 Virchow first noted that inflammatory cells are present 
within tumors and that tumors frequently arise at sites of 
chronic inflammation. Today we know that in the site of a 
chronic inflammation a toxic concentration of free radicals 
may facilitate the tumorigenesis by favoring DNA mutation 
accumulation (transformation) [23]. Thereafter, transformed 
cells rapidly proliferate producing small (400 µm in 
diameter) tumors in the absence of neoangiogenesis and thus 
generating a hypoxic microenvironment. Hypoxia has two 
effects on tumor cells: 1-necrosis of cells in the inner region 
of the tumor, more distant from host tissue vessels. 2-
adaptation of cells to the hypoxic gradient within the tumor 
through the activation of HIF1α and expression of many 
genes such as VEGF (which is important in tumor 
neoangiogenesis), Glut1 and HKII (which explain the 
metabolic remodeling of malignant tumors) and RAGE, 
P2X7, Toll-like, etc. (alarmin receptors) (Fig. 1) [1, 7, 8, 11, 
20, 24, 40-46]. Importantly, necrotic cells release alarmins 
(HMGB1, ATP/ADP, membrane debris, nucleic acids, etc.) 
that, by binding to their receptors, activate NFkB and 
hundreds of genes of the inflammatory reparative response 
(IRR) (Fig. 1) [45-60]. Therefore, transformed cells activate 
a gene response similar to that seen in activated leukocytes 
[44-46]. In solid human tumors (prostate ca [44], mammary 
ca [8, 43-46], glioblastoma [24] and thyroid papillary ca [61, 
62]) the upregulation of alarmin receptors and the increased 
expression of major IRR genes has been shown, comparing 
tumor with host normal LCMD tissue fractions, in the 
absence of leukocytes (CD45+ cells) [43-46, 61, 62]. 
 Hypoxic treatment of various tumor cell lines reproduces 
a gene adaptation similar to that seen in solid tumors, leading 
to the malignant phenotype [44-46]. Inhibition of HIF1α 
and/or NFkB in the same tumor cell lines prevents invasion 
and metastasis, suggesting a possibility to control tumor 
progression, by modulating inflammation through HIF1α 
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and NFkB inhibition. An early control of HIF1α and/or 
NFkB activity could lead to a more efficient and less toxic 
therapeutic approach, not eradicating the tumor, but rather 
controlling its progression [36]. 
 Presently, it is unclear if cancer stem cells can be the 
most susceptible target of these hypoxia-driven changes and 
if they can be blocked or controlled by modulating HIF1α 
and NFkB activity. 
Hypoxia and Inflammation in Thrombosis: Role of 
Arterial Occlusion and Infarction 
 Thrombus formation is a frequent cause of ischemic 
hypoxia due to the occlusion of an arterial vessel. Ischemia 
produces severe cell damage and necrosis in tissues due to 
shortage of oxygen and nutrients as it occurs in myocardial 
infarction and cerebral ictus [63, 64]. Similarly to what we 
have described in tumors, necrotic cells release alarmins, 
while in surviving cells HIF1α is activated, changing the cell 
phenotype with the expression of alarmin receptors and 
activation of NFkB [63, 65-67]. It is well known that a few 
hours after infarction, HMGB1 and other alarmins are 
released [64, 68] and myocardial tissue or cerebral tissue can 
be infiltrated by recruited and activated leukocytes, 
contributing to the amplification of inflammatory response, 
to salvage and repair of damaged tissue [64, 68, 69]. 
However, it is well known that a prolongation of this phase 
is harmful leading to a pathological remodeling of the 
myocardium [63, 65]. 
Hypoxia and Inflammation in Obesity: Role of Adipocyte 
Hypertrophy 
 Obesity is probably initiated by chronic overnutrition and 
decreased energy expenditure (sedentary lifestyle) [70]. At 
level of white adipose tissue (WAT) this imbalance leads to 
an accumulation of fat nutrients as lipid droplets in the 
cytoplasm of adipocytes which progressively undergo 
hypertrophy, leading to the increase of white fat mass or 
obesity. Inadequate metabolic homeostasis and insufficient 
vascular perfusion are responsible for cell stress, local 
hypoxia, HIF-dependent adaptation and necrosis of 
adipocytes that are more distant from vessels. Hypoxia 
progressively occurs as the ratio vessel/adipose tissue area 
decreases [70-72]. The activation of HIF1α produces 
metabolic changes favoring insulin-resistance and type II 
diabetes, production of ROS, and expression of TLRs, 
NLRs, RAGE and P2X7 all activating NFkB and a non-
leukocytic inflammatory response. The gene expression 
directed by NFkB includes cytokines, adipokines and 
chemokines, numerous classical inflammatory mediators and 
production of ROI and RNI. The latter two are responsible 
for adipocyte necrosis, while mediators activate resident 
leukocytes and recruits distant and circulating white cells, 
increasing the local inflammation firstly activated in 
adipocytes [73]. AT resident macrophages and lymphocytes 
may increase from less than 10% to more than 40% [73]. 
The involvement of distant organs (especially hepatocytes 
and skeletal muscle) creates a stable vicious metabolic circle 
maintaining local and systemic inflammation, aggravating 
insulin-resistance and metabolic dysfunctions, strongly 
contributing in this way to the pathogenesis of type II 
diabetes and metabolic syndrome [72, 74]. Adipocyte 
necrosis initially produced by ROI and RNI is relevant for 
IRR amplification and for AT fibrosis: necrotic adipocytes 
release alarmins which, acting on alarmin receptors of local 
adipocytes and resident leukocytes, activate and amplify 
local inflammation. Additionally IRR chronically stimulates 
repairing pathways, especially TGF-β pathway, leading to 
AT fibrosis [70]. 
Hypoxia and Inflammation in Diabetes Complications: 
Role of ECM and BM Thickness 
 Inflammation contributes to the primary pathogenesis of 
diabetes (i.e. damage of the insulin-producing β-cells and 
metabolic abnormalities increasing insulin-resistance), but it 
is as much relevant for the pathogenesis of the devastating 
complications including diabetic nephropathy, diabetic 
cardiomyopathy, retinopathy, great vessel involvement, 
peripheral arm and legs microvasculopathy and cerebral 
vasculopathy with brain hypotrophy [75]. All of them 
develop in association with a peculiar microvasculopathy 
due to an accumulation of AGEs, consequent hypoxia  
and inflammatory response with tissue damage. In the 
individual patient the severity of diabetes is not necessarily 
associated with high levels of hyperglycemia and metabolic 
abnormalities, but rather with these complications occurring 
preferentially in a specific organ or tissue, probably 
depending on individual susceptibility to non-enzymatic 
glycation and hence to the local accumulation of AGEs  
[74, 76]. 
 Due to diabetic hyperglycemia, proteins undergo heavy 
non-enzymatic glycation forming and accumulating AGEs. 
Slow turn-over, long-lasting proteins forming ECM and 
basement membranes may be particularly susceptible and 
relevant for the pathogenesis of microangiopathy, because 
they rapidly accumulate around the vessels, in the ECM and 
in basement membranes of tissues, thus increasing the 
distance between the lumen of vessels and the cells of tissue 
that need to be fed (nourished) with oxygen and nutrients  
by simple diffusion (Fig. 2). In this way a hypoxic 
microenvironment is generated activating HIF1α and 
inflammatory response. In diabetes a substantial contribution 
to the activation of NFkB arise from RAGE signaling. 
RAGE, firstly identified for its binding to AGEs, is an 
alarmin receptor constitutively expressed by CD45+ cells 
(leukocytes) or induced by HIF1α [45, 46, 77]. The natural 
specific ligand of RAGE, under normal conditions, is the 
cytokine/alarmin HMGB1 having the highest binding 
affinity [13], but in diabetes a phenomenon of spill-over 
occurs due to high concentrations of AGEs that may saturate 
RAGE. 
Hypoxia and Inflammation in Abnormal Hypertrophy 
with Insufficient Neoangiogenesis 
 Cell hypertrophy is an increase of cell volume due to 
abnormal synthesis of normal molecules and organelles, 
specific of a cell type. In physiologic myocardial hypertrophy 
[78, 79], such as that in trained athletes, sarcomere components, 
mitochondria and regulatory proteins harmonically increase 
leading to myocardiocyte volume increase with normal 
contractile function. Parallel vessels and stroma increased 
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and remodeled for an optimal contractile performance [78]. 
Abnormal hypertrophy, such as that occurring in 
hypertension or in loss-of-function mutation of sarcomeric 
proteins, increase of sarcomeric components overcome the 
mitochondrial, vessel and stroma adaptations, with abnormal 
organization of contractile fibrils (sarcomeric disarray with 
abnormal direction of the contractile force) [79]. Also in this 
case the ratio vessel area/myocardiocyte area is sharply 
decreased giving rise to a hypoxic condition similar to that 
seen in obesity. In different types of hypertrophic 
cardiomyopathy an insufficient vasculature and an increase 
of leukocytes have been described [80]. In conclusion, in 
various conditions of abnormal cell hypertrophy, with 
relative decrease of vascular perfusion the pathway HIF1α-
NFkB may be activated primarily by hypoxia, suggesting a 
role in the long-term damage of the tissue, leading to 
functional insufficiency and fibrosis. It is unknown if 
targeting HIF-NFkB pathway may have beneficial effects in 
slowing or blocking the progression of these conditions. 
Hypoxia and Inflammation in Storage and Neuro- 
degenerative Disease: Role of False Hypertrophy 
 False hypetrophy is a cell volume increase due to an 
abnormal accumulation of molecules and components that 
normally should be properly eliminated before an evident 
storage occurs. Adipocyte hypertrophy can be defined false 
hypertrophy, but a number of other diseases may show false 
hypertrophy with evident increase in cell volume, in parallel 
with accumulation of abnormal molecular components, 
depending on type of disease (Table 2) [71, 74, 81-90]. In 
storage diseases accumulation occurs in cytoplasm 
(glycogen) or in lysosomes (mucopolysaccarides, complex 
lipids and other molecules) and in several neurodegenerative 
diseases poliglutaminic proteins accumulate into the cytosol 
as monomeric forms or as polymeric fibrils (Huntington 
disease, Parkinson disease, etc.) [82-86, 91]. Abnormal 
proteins may be found as monomers, but more frequently as 
protease-resistant β-fibrils, both inside the cell (prion 
diseases) and/or in the extracellular space around the 
affected cells. In the Alzheimer disease β-fibrils originate 
from abnormal tau proteins and accumulate into the cytosol 
(tangles), but also originate from polymeryzation of secreted 
β-amyloid peptide, forming typical extracellular plaques 
[87]. In several other conditions, generally named β-
fibrillosis, in which an excess of abnormal β-sheet rich 
protein is synthesized, β-fibrils may polymerize and 
accumulate in the intracellular and extracellular space. 
 All these conditions have in common the false cell 
hypertrophy which establish in the tissue a progressively 
insufficient perfusion, giving rise to a hypoxic 
A        B 
 
Fig. (2). Diabetic nephropathy: increased thickness of basement membranes. A – Detail of a normal glomerulus in the basement membrane 
(BM) has an average thickness of 200-300 nm. B – Detail of diabetic kidney basement membranes and extracellular matrix (ECM): there is 
an average of ten-fold increase as compared to the normal. Collagen and ECM components are also augmented. BM = basement membrane; 
BME = basement membrane of the epithelial cells; BS = Bowman’s Space; DEBM = basement membrane of the capsular and tubular 
epithelium; E = endothelial cell; P = epithelial (podocyte) cell with foot processes; M = mesangial cell; PTE = proximal tubule epithelial 
cells; RC = red cell. 
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microenvironment and consequent activation of the HIF1α-
NFkB pathway, cell/tissue damage, chronic inflammation, 
repair and fibrosis. All these features have been described in 
the various phases of long-duration and slow progression of 
these diseases. For instance, we have evidences that in 
Fabry’s disease accumulation of glycolipid bodies causes 
false hypertrophy in myocardiocytes leading to a 
hypertrophic heart and in perivascular fibroblast, in vascular 
smooth muscle cells and in endothelial cells producing an 
evident reduction or obliteration of the vascular lumen which 
further contributes to the hypoxia [83]. 
Hypoxia and Inflammation in Chronic Inflammatory 
Diseases (Lung Injury, Inflammatory Bowel Diseases, 
Chronic Arthritis and Autoimmune Diseases) 
 Primary chronic inflammation, such that occurring in 
COPD, in inflammatory bowel diseases, in chronic arthritis 
and autoimmune diseases all have in common a primary IRR 
with impaired resolution and tissue damage leading to 
fibrosis and hypoxia [92, 93]. In these conditions initial 
inflammation and ROI and RNI production are probably the 
early events of the disease. Afterwards, the progressive 
edema, damage and fibrosis are the determinants for the 
activation of HIF/NFkB pathway and the maintenance of the 
chronic inflammation leading to the final insufficiency [92, 
93]. ROI and RNI are produced mainly by endogenous 
metabolism (80% of the oxygen is used by mitochondria) 
and by constitutive or inducible enzymes such NOS. 
Hypoxia and stimulation by GFs or cytokines contribute to 
activate free radical production, together with external 
factors such as radiations, UV, chemotherapy and activators 
of metabolism such as diet and physical activity (Fig. 3). 
Free radicals are highly reactive with all biological 
molecules and represent damaging agents for our cells. For 
this reason a number of highly redundant mechanisms and 
molecules have been selected by the evolution to control 
their intracellular harmful concentration [26]. Major ROS 
detoxifying mechanisms are represented in Fig. 3 and 
include cytosolic and mitochondrial SOD, Glutathione, 
peroxidases, redoxins and exogenous and dietary 
antioxidants. Intracellular bilirubin a byproduct of the 
hemeoxygenase 1 is an efficient scavenger in that 1 mole of 
bilirubin can inactivate 2000 moles of radicals [94]. 
 At physiological concentrations intracellular radicals are 
major modulators of several master transcription factors 
(Fig. 4) such as NFkB, AP-1, STAT3, Nrf2, HIF1α and 
others all involved in the hypoxia-related proinflammatory 
pathway involving HIF/NFkB [95-98]. 
 In summary such chronic inflammatory diseases are 
triggered and maintained by chronic inflammation with the 
aggravation of an hypoxic condition activating the 
HIF/NFkB pathway. 
Hypoxia and Inflammation in Ageing and Age-related 
Diseases 
 Aged tissues may become chronically relatively hypoxic 
due to ageing of vasculature, especially microvessels, and to 
the increase of fibrotic and abnormal components of stromal 
over parenchymal part. 
 Ageing is considered a progressive degradation of body 
functions over time, caused by a discrepancy between 
tissue/cell damage and the homeostatic ability to repair cells 
and restore the lost function. This results in the accumulation 
of molecular damage especially on DNA and proteins with 
the involvement of a number of important functions. For 
instance in ageing there is an increase in intracellular 
oxidative stress due from one side to the progressive 
decrease of the intracellular ROS scavenging, from the other 
side to an abnormal proinflammatory age-related chronic 
Table 2. Examples of false hypertrophy in which tissues undergo hypoxia for vasculature insufficiency.  
Disease	   Hypertrophy Pathogenesis	   Vasculature Alteration	   Hypoxic/inflammatory Features	   References	  
Obesity	   Lipid droplet accumulation in 
adipocytes	  
Insufficient vascular bed in 
white adipose tissue	  
HIF1α/NFkB activation; mediator 
and effector synthesis; increased 
resident leukocytes; fibrosis.	  
[37, 41, 49]	  
Lysosomal diseases	   Glycogen, complex lipid or 
mucopolysaccaride accumulation 
into lysosomes	  
Insufficient vascular bed when 
vessels are affected. Insufficient 
vasculature in advanced diseases 
with unaffected vessels	  
Increased tissue leukocytes; necrosis; 
fibrosis	  
[48, 52]	  
Cytosolic storage 
diseases	  
Glycogen, cristal  
(cystine, cholesterol, uric acid),  
fibril accumulation	  
Insufficient vascular bed in 
advanced diseases.	  
Increased tissue resident leukocytes; 
fibrosis	  
[50]	  
Neurodegenerative 
diseases	  
Neuronal hypertrophy for abnormal 
polyglutaminic or fibrillar protein 
accumulation into the cytosol 	  
Insufficient vascular bed only in 
advanced disease.	  
Increased tissue leukocytes, fibrosis	   [51, 52, 54]	  
Amyloidosis or  
β-fibrillosis	  
Intracellular and/or extracellular 
deposits of β-fibrils as polymers of 
abnormal peptides	  
Insufficient and compressed 
vessels by amyloidosic mass	  
Toll-like receptor activation; fibrosis	   [54] 
References are indicated and discussed in the text. 
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systemic state [99, 100]. The last one is produced by several 
synergic factors including a degraded control of IRR, the 
insurgence of new antigens (as abnormal/mutated proteins) 
causing various autoimmune diseases, an increase on AGEs 
which activate the alarmin receptor RAGE, and a systemic 
sublethal damage releasing HMGB1 and other endogenous 
alarmins. Due to the chronic and progressive accumulation 
of tissue damage, inefficient repairing mechanisms (the stem 
cell compartment is decreased in function and number of 
cells) privilege the formation of fibrotic healing with an 
accumulation of fibrous tissue in aged parenchymas. This 
general tissue degradation together with vasculature ageing 
may lead to a chronic hypoxic/proinflammatory condition 
similar to that seen before [101]. 
TARGETING HIF AND INFLAMMATION PATHWAYS 
AND MOLECULES 
 In this review the pathway HIF-NFkB has been indicated 
as the highway of signaling bridging hypoxia with 
inflammation leading to the associated damage, 
consequently, it appears relatively simple, in principle, to 
target the molecular component to modify the outcome of all 
the above mentioned diseases (Fig. 4). However, the problem 
is much more complex and challenging for many reasons: 
first, there are many secondary alternative pathways that can 
be activated if the main one is inhibited; second, we still do 
not know what is the toxicity and the unwanted side-effects 
of this therapeutic strategy; finally, some of these agents 
(especially inhibitors of HIF and NFkB) are natural products 
or off-label drugs which need to be endorsed on specific 
clinical trials for these diseases. 
Targeting HIF 
 HIF1α has become the target of an increasing number of 
inhibitors developed with the aim to block or reduce tumor 
growth and progression [102, 103] and that could also be 
useful in other hypoxia-related pathologies described above. 
The different mechanisms that can be exploited to achieve a 
significant HIF inhibition have been extensively detailed by 
us [36]. Here we will review the major molecules inhibiting 
HIF in vitro and/or in vivo. 
 HIF activity can be inhibited by preventing protein 
accumulation as in the case of the PI3 kinase inhibitor 
wortmannin or the mTOR inhibitor rapamycin [104, 105]. 
Similarly, HIF protein expression is inhibited by digoxin a 
cardiac glycoside [102] and by 2 methoxyestradiol (2ME2), 
a microtubule targeting agent that has been shown to inhibit 
HIF cytosol to nuclear shuttling [106]. HIF can also be 
inhibited by altering its post-translational modifications such 
as acetylation/deacetylation by using modulators of class II 
and class III, histone deacetylases (HDAC), the latter also 
known as sirtuins [107, 108]. Molecules falling in this 
category are trichostatin and resveratrol that modulate the 
activity of class II and class III HDAC, respectively. 
However, in this case, while class II HDAC inhibition 
determines an increased degradation of HIF by increasing its 
ubiquitination, the mechanism of action of sirtuins activators 
is more complex and less known. In fact, deacetylation of 
HIF by sirtuins and in particular SIRT1 and SIRT6 has been 
shown to deacetylate HIF thereby decreasing its 
transcriptional activity [107]. In addition sirtuins modulation 
is complicated by the fact that they also have and anti-
oxidative function with reduction of reactive oxygen species 
(ROS) production. Since HIF is stabilized by ROS 
accumulation, sirtuins inhibition of HIF is also achieved by 
preventing ROS accumulation in the cell [109, 110]. A large 
number of natural products have been shown to inhibit HIF 
by different mechanisms such as proteasomal degradation as 
in the case of curcumin [111], moracin O and P [112]; 
increased HIF degradation such as in the case of resveratrol 
[113, 114] and Sibiriquinone A [115]. HIF1α can be 
inhibited by preventing its dimerization to HIF1β as in the 
case of the antibacterial agent acriflavine [116], by inhibiting 
 
Fig. (3). Generation of ROS by endogenous or exogenous stimuli (red) and their major detoxifying mechanisms (green). [Modified from 26]. 
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its DNA binding as in the presence of doxorubicin or 
daunorubicin [117], or, finally, by preventing HIF1α binding 
to its coactivator p300 as in the case of chetomin or 
bortezomib [118, 119]. 
Targeting Alarmin Receptors 
 Alarmin receptors are localized on the cell surface 
(plasmamembrane) or on intracellular membranes (endosomes, 
phagosomes) and recognize repeated structures present in 
exogenous (microbes) or endogenous (host) molecules [13, 
120]. Classic members of the alarmin receptors are: receptor 
for advanced glycation endproducts (RAGE) and toll like 
receptors (TLRs). The main role of alarmin receptor is to 
recognize a molecular pattern associated either to the 
presence of a pathogen or to necrotic cells. The binding of 
alarmin receptors to their ligand results in the activation of 
an inflammatory response through the formation of 
inflammasome and engagement of NFkB [36, 61]. The 
observation that alarmin receptors are capable to initiate and 
propagate inflammation has made them attractive target for 
the treatment of many inflammatory diseases. 
 In the case of RAGE, strategies are focused on inhibiting 
its interaction with advanced glycation endproducts (AGEs), 
on blocking RAGE or on inhibiting its signaling [121]. In the 
first strategy, inhibition of AGE accumulation by molecules 
such as aminoguanidine (Pimagedine®), Pyridoxamine, a 
vitamin B complex, lysozyme and other AGE blocking 
agents result in amelioration of vascular functions and 
reduction of other complications observed in diabetic 
patients, in prevention of neuropathy and retinopathy in 
diabetic animal models and in reducing the severity of 
diabetic retinopathy [122]. 
 Blockage of RAGE has been successfully obtained by 
using the natural presence of a soluble form of RAGE 
(sRAGE). In fact, sRAGE synthesis is decreased under 
pathologic conditions such as coronary artery disease, 
 
Fig. (4). Targeting the HIF/NFkB pathway. SMI = small molecule inhibitors, means “specific” compunds that have shown a “specific” or 
“quasi-specific” inhibitory activity on a single member of the HIF/NFkB pathway. MoAb = monoclonal antibodies: they have been produced 
against a specific protein, showing a inhibitory effect on their biological action. The lists of these compounds and MoAbs and their relative 
references are extremely long and are out of the scope of this review. NSAIDs = non-steroidal antinflammatory drugs [28]. 
10    Endocrine, Metabolic & Immune Disorders - Drug Targets, 2015, Vol. 15, No. 3 Russo et al. 
hypertension, metabolic syndrome, arthritis and Alzheimer’s 
disease. Therefore, exogenous administration of sRAGE or 
of drugs such as angiotensin converting enzyme treatment or 
pioglitazone has shown beneficial effects in diabetic patients 
[121, 123]. 
 RAGE signaling blockage is a promising therapeutic 
target that has been observed in drugs such as metformin, an 
anti-hyperglycemic agent, that reduces protein glycation and 
also prevents NFkB activation by RAGE [122]. Other 
inhibitors of RAGE-axis are the dipeptidyl peptidase 4 (DPP 
4) inhibitors Sitagliptin, Alogliptin, and Vildagliptin that 
preserves the pancreatic β-cell function [124]. Finally, 
additional agents in clinical use with reported anti-RAGE 
effects are angiotensin 1 receptor blocker (Relmisartan), a 
dihydropyridine based calcium antagonist (Nifedipine) and 
prostacyclin analog (Beraprost sodium) [121]. 
 In the case of TLRs most of the studies demonstrating 
their role in human pathologies have been done in vitro or in 
animal models. In fact few molecules are approved for 
human use, one of this being imiquimod that has been 
approved for the treatment of genital warts, actinic keratosis 
and nonmelanoma skin cancers [125]. Its mechanism of 
action proceeds through activation of TLR7 and 8 with 
modulation of the immune response. However, the 
possibility to prevent or reduce inflammation-associated 
pathologies is linked to a better understanding of TLRs 
function that requires more research. In fact, mice lacking 
TLRs develop inflammatory diseases, such as arthritis, 
multiple sclerosis and inflammatory bowel disease. 
 On the other hand, TLR activation occurs early in the 
cascade of events that give rise to inflammation. Therefore, 
there might be an advantage in blocking them as they might 
give rise to chronic inflammation. Importantly, TLRs also 
detect products released from inflamed tissue, an event that 
feedback, on TLRs, leading to further activation. Breaking 
such a, positive feedback loop may be a highly effective 
strategy, to limit inflammation. From these considerations it 
is clear that both agonists and inhibitors of TLRs have been 
developed to prevent diverse human pathologies as 
extensively reviewed by Hennessy, 2010 [126]. 
 TLRs agonists have been studied to prevent cancer, viral 
and bacterial infections as well as for autoimmunity. In 
particular, single stranded RNA-based TLR7 and TLR8 
agonists have been used for the treatment of cancer and 
infectious diseases; CpG-based oligonucleotides that mimic 
unmethylated bacterial DNA are also being evaluated as 
potential anticancer drugs [127, 128]. Immune modulatory 
oligo nucleotides (IMOs) such as IMO-2055 have anticancer 
activity in a mouse model when used as a monotherapy and 
this activity was amplified when it was used in combination 
with chemotherapeutic agents [128]. 
 Noncoding DNA called MGN-1703 and MGN-1706 are 
double stem-loop immunomodulating adjuvants developed 
as anticancer TLR9 agonists. A purified, water soluble 
diphosphorylated and triacetylated lipid-A derived from E. 
coli known as OM-174 acts as a TLR4 agonist. It reduces 
tumour growth, increases IFNγ production and prolongs the 
survival of mice [129, 130]. The TLR2 agonist SMP-105 
that consists of cell-wall components, from Mycobacterium 
bovis (strain BCG/Tokyo), is approved for the treatment of 
bladder cancer. In mice, SMP-105 activates NFkB in a 
TLR2-dependent and TLR4-independent manner. Upon 
administration of the compound, TLR2 knockout mice 
showed impairment of TNF-α and IL-6 production as well as 
reduced tumor growth [131]. Resiquimod (R-848) is 
currently being evaluated for treating hepatitis C and other 
viral infections [132]. A small-molecule TLR7 agonist, 
ANA773, is under investigation for the potential treatment of 
hepatitis C infection and cancer [133]. Finally, vTX-1463 
reduced allergic responses through the suppression of a Th2-
mediated allergic response. When administered intranasally, 
it resulted in a decrease in the number of eosinophils and less 
congestion [126]. 
 Extensive research has been developed to search for 
TLRs antagonist as novel therapeutics. Derivatives and 
small-molecule analogues of antimalaria drugs chloroquine 
and quinacrine act as a TLR9 antagonist suppress activation 
of an immune response [134]. The quinazoline derivative 
CPG-52364 is an anti-inflammatory TLR antagonist which 
specifically inhibits TLR7, TLR8 and TLR9 and inhibits 
disease progression of autoimmune diseases in animal 
models [135]. TLR4 antagonistic antibodies are being 
developed to block immune signaling in diseases associated 
with an excessive immune response. The most advanced is 
NI-0101, which interferes with the dimerization of TLR4 
[136]. Similarly, 1A6 is an antibody that recognizes TLR4–
MD-2 and it delayed the development of colitis and reduced 
the inflammatory response in a mouse model. However, 
when the antibody was administered during the recovery 
stage of the disease it impaired mucosal healing [136]. 
Targeting Inflammasome 
 Pharmacological manipulation of inflammasome activity 
is under extensive investigation due to the central role of 
inflammasome components such as NLRs to mediate the 
response to PAMPS and DAMPS [137]. Currently, the best 
treatments for inflammasome disorders aim to target the 
main product of inflammasome activity, IL-1β. Inhibition of 
IL-1 may be achieved at different levels. Some substances 
such as monoclonal antibodies target IL-1 molecule directly 
(canakinumab, rilonacept, gevokizumab) while others are 
antagonists of IL-1 receptor (anakinra) [138, 139]. Other 
strategies for treating IL-1 related disease rely on antagonists 
of P2X7 receptor to treat LES and on caspase-1 inhibitors 
[140]. Small-molecule inhibitors of NLRP3 such as Glyburide 
are used in the treatment of T2D, where it inhibits IL-1β 
production by acting upstream of NLRP3. Parthenolide is a 
sesquiterpene lactone that has multiple anti-inflammatory 
properties. Separate to its effects on NFkB activation, 
parthenolide has now also been shown to inhibit caspase-1 
and NLRP3 [141]. 
 Bay11-7082 is another NFkB inhibitor that was also 
found to specifically inhibit NLRP3 by preventing the 
ATPase activity of NLRP3 [141]. Currently, available 
inhibitors of inflammasome function have either not been 
clinically successful or have multiple targets. Therefore, the 
development of small molecule inhibitors that directly target 
the NLRP3 inflammasome could provide a more efficient 
One Special Question to Start with: Can HIF/NFkB Endocrine, Metabolic & Immune Disorders - Drug Targets, 2015, Vol. 15, No. 3    11 
therapy for treating IL-1β and inflammasome-related 
diseases. 
 In conclusion, our understanding of the precise 
mechanism of the NLRP3 inflammasome is still scattered. 
However, given the importance of NLRP3 for inflammatory 
diseases, more information on its modulation will help our 
understanding of NLRP3 in disease and its potential 
therapeutic manipulation. 
Targeting NFkB and NFkB-dependent Genes 
 NFkB has a central role in the cellular response to 
inflammation: this transcription factor regulates the 
expression of hundreds of genes that, in turn, control a large 
number of intracellular pathways. As in the case of HIF, the 
importance of NFkB inhibition for the prevention or 
reduction of many human pathologies has been extensively 
reviewed by us [36]. Importantly, many NFkB inhibitors are 
off-label drugs already used in medicine or natural compounds. 
 Generally, inhibition of NFkB can be obtained by 
exploiting the diverse mechanisms controlling its stability 
due for example to post translational modifications or by 
preventing its nuclear translocation and accumulation. 
 In particular parthenolide, curcumin, aspirin and 
ibuprofen can inhibit NFkB by interacting and blocking IKK 
kinase that phosphorylates and activates NFkB [142-144]. 
Other IKK inhibitors are natural compounds such as B-
carboline derived from plants and anti-inflammatory drugs 
such as sulindac and sulfasalazine [145]. Finally, NFkB can 
be inhibited by using phosphatases activators such as 
cytosine arabinoside [146]. 
 Inhibition of proteosomal degradation of IkB, a 
regulatory protein that binds to NFkB and retains it in the 
cytoplasm, results in the inhibition of NFkB activity. 
Bortezomib is the most studied since has shown some 
important results in reducing tumor growth when used as a 
adjuvant to standard chemotherapy [147]. These results have 
lead to the synthesis of new proteasome inhibitors such as 
carfilzomib and salinosporamide that can be used at 
nanomolar ranges with lower toxicity [148, 149]. 
 Acetylation/deacetylation of NFkB is another post-
translational modification that can be influenced to regulate 
NFkB activity. In particular, since acetylation activates 
NFkB, inhibitors of acetyl transferases such as p300 or 
activators of deacetylases such as sirtuins as been shown to 
prevent NFkB activation and the following inflammation, 
tumor growth, etc. [149]. 
 Finally, NFkB activity can be regulated by preventing its 
nuclear shuttling and accumulation. Very few substances  
can inhibit NFkB nuclear translocation and more studies  
are needed. However, dehydroxymethylepoxyquinomicin 
(DHMEQ) derived from an antibiotic has shown anti-
inflammatory and anti-tumoral activity by preventing nuclear 
accumulation of NFkB [150]. 
CONCLUSIONS 
 Hypoxia and inflammation are strictly and sequentially 
related at the molecular, cellular, and clinical levels. They 
have a crucial role in pathogenesis of a number of severe and 
widespread chronic diseases which in Western countries are 
increasing with the life expectancy. Pathways including 
oxygen sensing mechanisms, HIF-dependent genes, IRR 
activation and NFkB-dependent genes are potential 
therapeutic targets for the treatment of devastating diseases 
such as cancer, cardiovascular diseases, diabetes, obesity, 
neurodegenerative diseases and a number of other chronic 
invalidating inflammatory diseases. 
 However, such approaches should be clinically tested in 
all other patients in which hypoxia has been demonstrated to 
activate chronic inflammation, such as acute lung injury, 
myocardial ischemia and inflammatory intestinal disease. 
Finally, targeting hypoxia-dependent signaling pathways 
could also help attenuate organ failure due to ischemia in 
patients undergoing major surgery or alleviate hypoxia-
driven graft inflammation after solid-organ transplantation. 
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LIST OF ABBREVIATIONS 
AGEs = advanced glycation end-products 
AP1 = Activating protein 1 
AT = Adipose tissue 
COPD = Chronic Obstructive Pulmonary Disease 
DAMPS = Damage-Associated Molecular Patterns 
HIF = Hypoxia inducible factor 
HMGB1 = high mobility group box 1 
JAK = Janus kinase 
LCMD = Laser capture microdissection 
NLR = NOD-like receptors 
NFkB = Nuclear factor 
PAMPs = Pathogen-Associated Molecular Patterns 
P2X7 = Purinergic receptor 2X7 
RAGE = receptor for advanced glycation end 
products 
ROI = Reactive Oxygen Intermediates 
RNI = Reactive Nitrogen Intermediates 
SOCS = suppressor of cytokine signaling 
STAT = Signal transducers and activators of 
transcription 
TERT = Telomerase reverse transcriptase 
TF = transcription factor 
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TD2 = type 2 diabetes 
VEGF = vascular endothelial growth factor 
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